LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
33 funds hold it · Insiders net selling
Net selling: insiders sold $6.3M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $1K to $15K in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 2, 2026
Financial period
Q3 2026
Earnings per share
$4.78 expected
Revenue
$3.43B expected
FY 2026 guidance
$13.15B to $13.25B
No comparable estimate
Estimates as of Nov 8, 2026
EPS expected
$4.04 to $5.22
Revenue expected
16 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 2, 2026 | $4.76est. $4.78 | -0.50%in line | $3.44Best. $3.43B+0.30% | +11.8%from $3.08B |
| Jun 30, 2026Reported Aug 3, 2026 | $4.73est. $4.75 | -0.32%in line | $3.33Best. $3.22B+3.43% | +12.5%from $2.96B |
| Mar 31, 2026Reported May 4, 2026 | $4.47est. $4.31 | +3.81%beat | $2.99BSEC filing | +7.8%from $2.77B |
| Dec 31, 2025Reported Feb 12, 2026 | $5.03est. $5.15 | -2.30%miss | $3.23BAlpha Vantage | +10.8%from $2.91B |
| Sep 30, 2025Reported Nov 3, 2025 | $4.80est. $4.58 | +4.80%beat | $3.08BSEC filing | +11.0%from $2.77B |
| Jun 30, 2025Reported Aug 4, 2025 | $4.52est. $4.25 | +6.35%beat | $2.96BSEC filing | +12.1%from $2.65B |
| Mar 31, 2025Reported May 5, 2025 | Not on file | No estimate | $2.77BSEC filing | +3.0%from $2.69B |
| Dec 31, 2024Reported Feb 10, 2025 | $3.98est. $4.02 | -0.99%in line | $2.91BAlpha Vantage | +15.7%from $2.52B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $3.23B | $2.99B | $3.33B | $3.44B |
| Cost of what it sold | $466.0M | $392.8M | $489.2M | $526.1M |
| Gross profit | $2.76B | $2.59B | $2.84B | $2.91B |
| What it spent | ||||
| Research and development | $973.7M | $961.6M | $993.8M | $1.32B |
| Sales and admin | $487.0M | $493.7M | $582.2M | $844.1M |
| Other operating costs | — | — | $21.8M | $37.1M |
| Total operating expenses | $1.46B | $1.46B | $1.60B | $2.20B |
| What was left | ||||
| Operating profit | $1.30B | $1.14B | $1.25B | $712.9M |
| Interest on debt | $3.3M | — | — | $36.0M |
| Profit before tax | $1.33B | $1.25B | $1.39B | $783.4M |
| Tax | $139.9M | $221.5M | $292.0M | $129.8M |
| Net profit | $1.19B | $1.03B | $1.10B | $653.6M |
| EBITDA | $1.39B | $1.31B | $1.45B | $819.4M |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Vir’s hepatitis delta combo tamps down virus as Gilead showdown looms
NeutralNov 9Evotec stock narrows Q3 loss as Horizon savings advance
Leans bullishNov 9Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment
BullishNov 9Alpha Cognition appoints Caren Deardorf to its board of directors
Leans bullishNov 9Alpha Cognition Appoints Former Biogen Executive Caren Deardorf to Board of Directors
Leans bullishNov 9Alpha Cognition Strengthens Its Board of Directors with Appointment of Caren Deardorf
BullishNov 9Weekly Recap: Higher 2026 revenue guidance and lower earnings
Leans bullishNov 9Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
NeutralNov 833 macro signals shaping VRTX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
